These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34543885)

  • 1. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
    Lilianty J; Bateman JF; Lamandé SR
    Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 editing to generate a heterozygous COL2A1 p.G1170S human chondrodysplasia iPSC line, MCRIi019-A-2, in a control iPSC line, MCRIi019-A.
    Kung LHW; Sampurno L; Yammine KM; Graham A; McDonald P; Bateman JF; Shoulders MD; Lamandé SR
    Stem Cell Res; 2020 Oct; 48():101962. PubMed ID: 33002832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a heterozygous COL2A1 (p.R989C) spondyloepiphyseal dysplasia congenita mutation iPSC line, MCRIi001-B, using CRISPR/Cas9 gene editing.
    Lilianty J; Nur Patria Y; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 May; 45():101843. PubMed ID: 32446218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using CRISPR/Cas9 to generate a heterozygous COL2A1 p.R719C iPSC line (MCRIi019-A-6) model of human precocious osteoarthritis.
    Yammine KM; Mirda Abularach S; Sampurno L; Bateman JF; Lamandé SR; Shoulders MD
    Stem Cell Res; 2023 Mar; 67():103020. PubMed ID: 36682125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing.
    Hosseini Far H; Patria YN; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 May; 37():101449. PubMed ID: 31075690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 gene editing of a SOX9 reporter human iPSC line to produce two TRPV4 patient heterozygous missense mutant iPSC lines, MCRIi001-A-3 (TRPV4 p.F273L) and MCRIi001-A-4 (TRPV4 p.P799L).
    Nur Patria Y; Stenta T; Lilianty J; Rowley L; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 Oct; 48():101942. PubMed ID: 32771907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling of dilated cardiomyopathy by establishment of isogenic human iPSC lines carrying phospholamban C25T (R9C) mutation (UPITTi002-A-1) using CRISPR/Cas9 editing.
    Barndt RJ; Ma N; Tang Y; Haugh MP; Alamri LS; Chan SY; Wu H
    Stem Cell Res; 2021 Oct; 56():102544. PubMed ID: 34583280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of two induced pluripotent stem cell lines (TMOi001-A-5, TMOi001-A-6) carrying variants in DISC1 exon 2 using CRISPR/Cas9 gene editing.
    Heider J; Sperlich D; Vogel S; Breitmeyer R; Volkmer H
    Stem Cell Res; 2022 Oct; 64():102925. PubMed ID: 36154917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a heterozygous TPM1-E192K knock-in human induced pluripotent stem cell line using CRISPR/Cas9 system.
    Kang JY; Mun D; Chun Y; Kim H; Yun N; Lee SH; Joung B
    Stem Cell Res; 2022 Aug; 63():102878. PubMed ID: 35917600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of a gene-corrected isogenic iPSC line (AHQUi001-A-1) from a patient with familial hypertriglyceridemia (FHTG) carrying a heterozygous p.C310R (c.928 T > C) mutation in LPL gene using CRISPR/Cas9.
    Sun X; Zhou X; Dong B; Wang C; Xiao X; Wang Y
    Stem Cell Res; 2021 Apr; 52():102230. PubMed ID: 33592566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of a human iPSC line and gene-corrected isogenic line derived from a patient with a CELF2 gene mutation.
    Hua M; Williams L; Burns K; Liu S; Ellis J; Innes AM; McPherson M; Yang G
    Stem Cell Res; 2024 Apr; 76():103344. PubMed ID: 38364506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a ST3GAL3 null mutant induced pluripotent stem cell (iPSC) line (UKWMPi002-A-3) by CRISPR/Cas9 genome editing.
    Diouf D; Vitale MR; Zöller JEM; Pineau AM; Klopocki E; Hamann C; Ziegler GC; Vanmierlo T; Van den Hove D; Lesch KP
    Stem Cell Res; 2023 Mar; 67():103038. PubMed ID: 36746102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of a gene-corrected human isogenic line (UAMi006-A) from propionic acidemia patient iPSC with an homozygous mutation in the PCCB gene using CRISPR/Cas9 technology.
    Fulgencio-Covián A; Álvarez M; Pepers BA; López-Márquez A; Ugarte M; Pérez B; van Roon-Mom WMC; Desviat LR; Richard E
    Stem Cell Res; 2020 Dec; 49():102055. PubMed ID: 33128956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of heterozygous (MRli003-A-3) and homozygous (MRli003-A-4) TRPM4 knockout human iPSC lines.
    Zhang F; Meier AB; Lipp P; Laugwitz KL; Dorn T; Moretti A
    Stem Cell Res; 2022 Apr; 60():102731. PubMed ID: 35245852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a human induced pluripotent stem cell line JHUi003-A with homozygous mutation for spinocerebellar ataxia type 12 using genome editing.
    Feng H; Li Q; Margolis RL; Li PP
    Stem Cell Res; 2021 May; 53():102346. PubMed ID: 34087983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line.
    Howden S; Hosseini Far H; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 Jul; 38():101453. PubMed ID: 31082677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a human induced pluripotent stem cell line JHUi004-A with heterozygous mutation for spinocerebellar ataxia type 12 using genome editing.
    Liu HB; Dong T; Deng L; Zhou C; Tang F; Margolis RL; Li PP
    Stem Cell Res; 2024 Jun; 77():103441. PubMed ID: 38759410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Derivation of induced pluripotent stem cells line (RCPCMi007-A-1) with inactivation of the beta-2-microglobulin gene by CRISPR/Cas9 genome editing.
    Bogomiakova ME; Sekretova EK; Eremeev AV; Shuvalova LD; Bobrovsky PA; Zerkalenkova EA; Lebedeva OS; Lagarkova MA
    Stem Cell Res; 2021 Aug; 55():102451. PubMed ID: 34237591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of a SOX9-tdTomato reporter human iPSC line, MCRIi001-A-2, using CRISPR/Cas9 editing.
    Nur Patria Y; Lilianty J; Elefanty AG; Stanley EG; Labonne T; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 Jan; 42():101689. PubMed ID: 31884373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.